(City)

(Last)

(Street)

(State)

(First) 780 THIRD AVENUE, 37TH FLOOR

DEERFIELD MANAGEMENT COMPANY,

1. Name and Address of Reporting Person*

L.P. (SERIES C)

(Zip)

(Middle)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

OMB APPROVAL OMB Number: 3235-0104 0.5

				S	ECURITIES				ll	er response:	
			Filed pursuant or Secti	to Section 1 on 30(h) of t	6(a) of the Securities Exchange the Investment Company Act of 1	Act of 1934 1940					
Flynn James E			2. Date of Event Requiring Statement (Month/Day/Year) 02/15/2018		3. Issuer Name and Ticker or Trading Symbol CATALYST BIOSCIENCES, INC. [CBIO]						
(Last) (First) (Middle) 780 THIRD AVENUE, 37TH FLOOR			<i>J2</i> /13/2010		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title v Other (specify)			If Amendment, Date of Original Filed (Month/Day/Year) Individual or Joint/Group Filing (Check			
(Street) NEW YORK NY 10017				below) Possible Member of 10% Group				Applicable Line) Form filed by One Reporting Pers X Form filed by More than One Reporting Person			
(City)	(State) (Zip)			D	- Committee Description	U O					
		<u> </u>	abie i - Non		ve Securities Beneficial	Ť					
1. Title of Securit	y (Instr. 4)				Amount of Securities eneficially Owned (Instr. 4)	3. Ownersl Form: Dire or Indirect (Instr. 5)	ct (D)	4. Nat (Instr.		t Beneficial Ownersh	
Common stock					859,307	I	Thro		hrough Deerfield Partners, L.P.(1)(2)		
Common stock					325,693	I		Through Deerfield Specia Fund, L.P. ⁽¹⁾⁽²⁾		d Special Situation	
		(e.ç			e Securities Beneficially nts, options, convertible		s)				
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable an Expiration Date (Month/Day/Year)		3. Title and Amount of Secur Underlying Derivative Secur	rity (Instr. 4) Conve		ercise	e Form:	6. Nature of Indired Beneficial Owners (Instr. 5)	
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price Deriva Secur	ative	Direct (D) or Indirect (I) (Instr. 5)		
1. Name and Addr	ess of Reporting Person [*] ; <u>E</u>										
(Last) 780 THIRD AV	(First) /ENUE, 37TH FLOOR	(Middle)									
(Street) NEW YORK	NY	10017									
(City)	(State)	(Zip)									
1. Name and Addr Deerfield M	ess of Reporting Person [*]										
(Last) 780 THIRD AV 37TH FLOOR	(First) /ENUE	(Middle)									
(Street) NEW YORK	NY	10017									

NEW YORK	NY	10017					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person* DEERFIELD PARTNERS, L.P.							
(Last) (First) (Middle) 780 THIRD AVENUE 37TH FLOOR							
(Street) NEW YORK	NY	10017					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person* Deerfield Special Situations Fund, L.P.							
(Last) (First) (Middle) 780 3RD AVENUE 37TH FLOOR							
(Street) NEW YORK	NY	10017					

Explanation of Responses:

1. This Form 3 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. and Deerfield Special Situations Fund, L.P. (collectively, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.

2. In accordance with Instruction 5 (b)(iv) to Form 3, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Remarks:

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Pr Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.

> /s/ Jonathan Isler, Attorney-in-02/15/2018 **Fact**

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Joint Filer Information

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Names:

Deerfield Partners, L.P., Deerfield Special Situations Fund, L.P.

Address: 780 Third Avenue, 37th Floor

New York, NY 10017

Designated Filer: James E. Flynn

Issuer and Ticker Symbol: Catalyst Biosciences, Inc. [CBIO]

Date of Event Requiring Statement: February 15, 2018

The undersigned, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Special Situations Fund, L.P., are jointly filing the attached Initial Statement of Beneficial Ownership on Form 3 with James E. Flynn with respect to the beneficial ownership of securities of Catalyst Biosciences, Inc.

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

Signatures:

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P. DEERFIELD SPECIAL SITUATIONS FUND, L.P.

By: Flynn Management LLC, General Partner By: Deerfield Mgmt, L.P., General Partner

By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact